
    
      PRIMARY OBJECTIVES: To determine the response rate of r-ATG and CsA in the first line
      setting. SECONDARY OBJECTIVES: To determine the level of IS as assessed by Immuknow assay in
      responders and compare it to non-responders. OUTLINE:Patients receive anti-thymocyte globulin
      IV over 4-24 hours daily on days 1-5. Beginning on day 6, patients receive oral cyclosporine
      twice daily for 6 months followed by a taper. Treatment continues in the absence of disease
      progression or unacceptable toxicity.
    
  